Loading...
•
Dec 31, 2021
Akebia Q4 2021 Earnings Report
Akebia's Q4 2021 financial results were reported, showing increased product revenue and collaboration revenue, and the company highlighted its readiness for the potential launch of vadadustat.
Key Takeaways
Akebia Therapeutics reported Q4 2021 financial results, with total revenue of $59.6 million, driven by net product revenue of $42.1 million and collaboration revenue of $17.5 million. The company's net loss was $70.7 million. Akebia is preparing for the potential launch of vadadustat, pending FDA approval.
Total revenue for Q4 2021 was $59.6 million, compared to $56.7 million for Q4 2020.
Net product revenue for Q4 2021 was $42.1 million, a 22% increase compared to $34.6 million for Q4 2020.
Collaboration revenue for Q4 2021 was $17.5 million, compared to $22.1 million for Q4 2020.
Net loss for Q4 2021 was $70.7 million, compared to $87.0 million for Q4 2020.
Revenue by Segment
Forward Guidance
Akebia expects continued Auryxia revenue growth in 2022 and is preparing for the potential commercial launch of vadadustat, pending FDA approval.
Positive Outlook
- Potential approval of vadadustat by the FDA.
- Potential first-in-class commercial launch of vadadustat in the U.S.
- Expectations regarding net product revenue growth for Auryxia in 2022.
- Ability of Akebia’s pre-commercialization activities to ensure patient access for vadadustat.
- Plans to secure reimbursement for vadadustat under TDAPA.
Challenges Ahead
- Timing of any regulatory approvals is uncertain.
- Interactions with the FDA, including reviews and inspections, can impact approval.
- The direct or indirect impact of the COVID-19 pandemic on Akebia’s business, operations, and the markets.
- Potential generic entrants for Auryxia and vadadustat.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...